{"id":{"repo_id":"wfu","oai_identifier":"oai:wakespace.lib.wfu.edu:10339/82205"},"canonical_url":"https://search.dev.ndltd.org/etd/wfu/oai:wakespace.lib.wfu.edu:10339/82205","repository":{"repo_id":"wfu","name":"Wake Forest University","base_url":"https://wakespace.lib.wfu.edu/oai/request"},"display":{"title":"SILVER NANOPARTICLES ARE EFFECTIVE FOR THE TREATMENT OF CLAUDIN LOW BREAST CANCER AND OTHER MESENCHYMAL CANCERS WITH HIGH ZEB1 EXPRESSION","abstract":"A woman’s lifetime risk of being diagnosed with breast cancer is approximately 1 in 8, and it is estimated that over 40,000 women will die from BC in 2017. With advances in molecular profiling, breast cancer has been divided into 5 molecular subtypes (luminal A, luminal B, HER-2 overexpressing, basal-like, and claudin-low) that have distinct genetic aberrations, morphological features, prognoses, and therapeutic responses. Therefore, breast cancer should be treated with subtype specific therapies as these may provide the greatest therapeutic benefit.","abstract_html":"A woman’s lifetime risk of being diagnosed with breast cancer is approximately 1 in 8, and it is estimated that over 40,000 women will die from BC in 2017. With advances in molecular profiling, breast cancer has been divided into 5 molecular subtypes (luminal A, luminal B, HER-2 overexpressing, basal-like, and claudin-low) that have distinct genetic aberrations, morphological features, prognoses, and therapeutic responses. Therefore, breast cancer should be treated with subtype specific therapies as these may provide the greatest therapeutic benefit.","abstract_has_math":false,"creators":["Swanner, Jessica Lynn"],"institution":"Wake Forest University","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2017,"date_issued":"2017","date_published":"2017","updated_at":"2026-07-27T22:02:11Z","subjects":["breast cancer"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10339/82205","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Swanner, Jessica Lynn"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2017-06-15T08:35:59Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2018-06-14T08:30:10Z"]},{"key":"dc:date.issued","label":"Date","values":["2017"]},{"key":"dc:publisher","label":"Institution","values":["Wake Forest University"]},{"key":"dc:type","label":"Dc Type","values":["Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["breast cancer"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/10339/82205"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["A woman’s lifetime risk of being diagnosed with breast cancer is approximately 1 in 8, and it is estimated that over 40,000 women will die from BC in 2017. With advances in molecular profiling, breast cancer has been divided into 5 molecular subtypes (luminal A, luminal B, HER-2 overexpressing, basal-like, and claudin-low) that have distinct genetic aberrations, morphological features, prognoses, and therapeutic responses. Therefore, breast cancer should be treated with subtype specific therapies as these may provide the greatest therapeutic benefit."]},{"key":"dc:title","label":"Title","values":["SILVER NANOPARTICLES ARE EFFECTIVE FOR THE TREATMENT OF CLAUDIN LOW BREAST CANCER AND OTHER MESENCHYMAL CANCERS WITH HIGH ZEB1 EXPRESSION"]}]}],"canonical_facts":{"dc:creator":["Swanner, Jessica Lynn"],"dc:date.accessioned":["2017-06-15T08:35:59Z"],"dc:date.available":["2018-06-14T08:30:10Z"],"dc:date.issued":["2017"],"dc:description.abstract":["A woman’s lifetime risk of being diagnosed with breast cancer is approximately 1 in 8, and it is estimated that over 40,000 women will die from BC in 2017. With advances in molecular profiling, breast cancer has been divided into 5 molecular subtypes (luminal A, luminal B, HER-2 overexpressing, basal-like, and claudin-low) that have distinct genetic aberrations, morphological features, prognoses, and therapeutic responses. Therefore, breast cancer should be treated with subtype specific therapies as these may provide the greatest therapeutic benefit."],"dc:identifier.uri":["http://hdl.handle.net/10339/82205"],"dc:language.iso":["en"],"dc:publisher":["Wake Forest University"],"dc:subject":["breast cancer"],"dc:title":["SILVER NANOPARTICLES ARE EFFECTIVE FOR THE TREATMENT OF CLAUDIN LOW BREAST CANCER AND OTHER MESENCHYMAL CANCERS WITH HIGH ZEB1 EXPRESSION"],"dc:type":["Dissertation"]},"updated_at":"2026-07-27T22:02:11Z"}